Edition:
United Kingdom

People: Aimmune Therapeutics Inc (AIMT.OQ)

AIMT.OQ on NASDAQ Stock Exchange Global Select Market

21.10USD
25 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$21.10
Open
$20.78
Day's High
$21.17
Day's Low
$20.57
Volume
137,194
Avg. Vol
215,019
52-wk High
$36.12
52-wk Low
$19.78

Haumann, Brett 

Dr. Brett K. Haumann is Director of the Company. Dr. Haumann is Chief Medical Officer and Senior Vice President, Clinical Development, at Theravance Biopharma. Prior to joining Theravance Inc. in 2013, Dr. Haumann served as Chief Medical Officer of the UK allergy company Circassia Limited. He also spent more than a decade with GlaxoSmithKline, where, as Vice President of Clinical Development, he was responsible for late-stage development of medicines for asthma and chronic obstructive pulmonary disease (COPD). He began his industry career with Glaxo Wellcome in the United Kingdom and South Africa, after working as an internal medicine practitioner and clinical researcher in South Africa. Dr. Haumann earned his Bachelor in Medicine and Surgery (M.B.B.Ch.) at the University of Witwatersrand Medical School, South Africa, and he holds an M.B.A. from Open University, United Kingdom.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --